AQST SVP has 1,667 shares withheld for RSU taxes

Aquestive Therapeutics, Inc. executive Melina Cioffi, SVP of Regulatory Affairs, reported a routine tax-related share disposition.

Rhea-AI Filing Summary

Aquestive Therapeutics, Inc. executive Melina Cioffi, SVP of Regulatory Affairs, reported a routine tax-related share disposition. On the transaction date, 1,667 shares of common stock were withheld by the company at $4.17 per share to cover tax obligations from vesting RSUs. After this withholding, Cioffi directly holds 273,200 shares of common stock, indicating the event is part of equity compensation mechanics rather than an open-market sale.

Insider Trade Summary

Exercise Price or Tax Liability: 1,667 shares

Exercise Price or Tax Liability 1 txn

Insider Cioffi Melina

Role SVP, Regulatory Affairs

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	1,667	$4.17	$7K

Holdings After Transaction: Common Stock — 273,200 shares (Direct)

Footnotes (1)

1. F1. Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

Key Figures

Shares withheld for taxes: 1,667 shares Withholding price per share: $4.17 per share Shares held after transaction: 273,200 shares

3 metrics

Shares withheld for taxes 1,667 shares Tax-withholding disposition for vesting RSUs

Withholding price per share $4.17 per share Value applied to withheld shares

Shares held after transaction 273,200 shares Direct common stock holdings post-transaction

Key Terms

Restricted Stock Units ("RSUs"), tax withholding obligation, Form 4

3 terms

Restricted Stock Units ("RSUs") financial

"in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

tax withholding obligation financial

"withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation"

Form 4 regulatory

"What did Aquestive Therapeutics (AQST) executive Melina Cioffi report on this Form 4?"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aquestive Therapeutics (AQST) executive Melina Cioffi report on this Form 4?

Melina Cioffi reported a tax-related share disposition. The company withheld 1,667 common shares to cover her tax obligations from vesting Restricted Stock Units, rather than an open-market sale, leaving her with 273,200 directly held shares afterward.

How many Aquestive Therapeutics (AQST) shares were withheld for Melina Cioffi’s taxes?

The filing shows 1,667 common shares were withheld. These shares were used to satisfy Melina Cioffi’s tax withholding obligation in connection with vesting RSUs, reflecting a standard equity compensation event instead of discretionary selling in the market.

What price per share was used for the tax withholding in the AQST Form 4?

The tax-withholding disposition used a price of $4.17 per share. This value applies to the 1,667 common shares withheld by the issuer to cover Melina Cioffi’s tax obligations tied to previously granted Restricted Stock Units that vested.

How many Aquestive Therapeutics (AQST) shares does Melina Cioffi hold after this transaction?

After the tax withholding, Melina Cioffi directly holds 273,200 common shares. This post-transaction balance, disclosed in the Form 4, indicates she retains a substantial equity position following the routine RSU-related tax-settlement event.

Was the AQST Form 4 transaction an open-market sale by Melina Cioffi?

No, it was not an open-market sale. The Form 4 describes an F-code tax-withholding disposition, where 1,667 shares were withheld by the issuer to pay Melina Cioffi’s tax obligations from vesting RSUs, a common administrative equity event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 12:36 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cioffi Melina

(Last) (First) (Middle)

C/O AQUESTIVE THERAPEUTICS, INC.

30 TECHNOLOGY DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Regulatory Affairs

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		F		1,667(1)	D	$4.17	273,200	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

Remarks:

	/s/ Thomas Zalewski, as Attorney-In-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)